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http://dx.doi.org/10.1016/j.jot.2013
2214-031X/Copyright ª 2013, The Aut
license (http://creativecommons.org/Abstract Due to the ageing population there is an increasing incidence of hip fractures in the
elderly. Oral nutritional supplements are being widely used to improve clinical outcomes and
mortality post-hip fractures. The aim of this study was to review the available literature on the
effects of oral nutritional supplements on elderly patients with hip fractures. A search of EM-
BASE (1988epresent) and MEDLINE (1946epresent) with the search terms: “nutritional supple-
ment” AND “hip fracture”; “nutritional supplement” AND “femoral neck fracture”;
“nutritional supplement” AND “intertrochanteric fracture”; “nutritional supplement” AND
“subcapital fracture”; “hip fracture” AND “vitamin supplement”; “hip fracture” AND “protein
supplement”; “hip fracture” AND “nutrient supplement” was carried out. Additionally, the
reference lists of articles were searched for relevant areas of study. Few studies showed that
oral nutritional supplementation led to a more positive clinical outcome amongst elderly pa-
tients suffering hip fractures. Most studies found little or nil positive results. Thus, the role
of oral nutritional supplementation on post-hip fracture mortality, infection/complication
rates, and hospitalisation/rehabilitation time amongst elderly patients is unclear. There is a
need for a broader, randomised, placebo-controlled clinical trial on the effect of oral nutri-
tional supplements and particularly on the supplements used commonly.
Copyrightª 2013, The Authors. Published by Elsevier (Singapore) Pte Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
With the ageing population expected to reach 25% of the
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hors. Published by Elsevier (Singa
licenses/by-nc-nd/4.0/).demand on hospital services [1]. The incidence of hip
fractures is also increasing, with one study projecting an
increase by 15% every 5 years until 2036, and by 10% every 5
years after that until 2051 [2]. Morbidity and mortalityTel.: þ61 285667166.
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ONS in the elderly with hip fractures 27following hip fractures are high, with mortality rates of 24%
being seen within the 1st year post-fracture. Protein energy
malnutrition is seen more often in patients suffering from
hip fractures than their age-matched control comparisons
[3]. Theoretically, by providing the malnourished elderly
patient with nutritional supplements, it is supposed that
their clinical outcomes may be improved.
The benefit of oral nutritional supplements (ONSs) in this
clinical scenario has been a topic of debate. Many trials
have found that ONSs indeed reduce hospital length [4],
pressure ulcers [5], economic cost [4], mortality [6,7], and
rates of infections or complications [6,8e10]. Postoperative
complications are described as a wide range of individual
conditions including wound infections, other infections
[e.g., pneumonia, urinary tract infection (UTI)], deep vein
thrombosis (DVT), pulmonary embolism (PE), myocardial
infarction, bedsores, delirium, severe anaemia, gastroin-
testinal (GI) ulcer, and cardiac failure. Others have found
little or no benefit of oral supplements [11,12]. Despite
their somewhat unclear benefit, a large variety of ONSs are
available on the market.
The aim of this review is to analyse the available liter-
ature on the effects of nutritional supplements on the
clinical outcomes (including mortality) of elderly patients
suffering from a hip fracture.Methods
A search of EMBASE (1988epresent) and MEDLINE (1946e
present) with the search terms: “nutritional supplement”
AND “hip fracture”; “nutritional supplement” AND “femoral
neck fracture”; “nutritional supplement” AND “inter-
trochanteric fracture”; “nutritional supplement” AND
“subcapital fracture”; “hip fracture” AND “vitamin sup-
plement”; “hip fracture” AND “protein supplement”; “hip
fracture” AND “nutrient supplement” was carried out.
Additionally, reference lists of articles were searched for
relevant areas of study. The exclusion criterion included
studies that did not use nutritional supplements, studies
that did not focus on hip fractures, and studies that did not
examine complications/outcomes that were affected by
the use of nutritional supplements. The inclusion criterion
was studies that focused on the effect of nutritional sup-
plements on the clinical outcome of patients with hip
fractures. The searches resulted in 94 EMBASE and 92
MEDLINE results. The authors manually sorted through the
available literature to identify 12 studies that fit the in-
clusion criteria.Results
Study participant profiles
All studies had set inclusion and exclusion criteria to
determine the eligibility of the patient to participate in the
identified study. Patient age varied from >60 years
[13e17], >65 years [18], and >70 years [19]. Fabian et al.
[20] included female patients >65 years and Sullivan et al.
[21] included all patients >64 years, whereas Bastow et al.
[3] included all “elderly” female patients with ages rangingfrom 68 years to 92 years. Most studies had time constraints
in which the patient had to receive the surgical invention
by, ranging from within 48 h [14,19], within 3 days [21], up
to within 2 weeks [17], 3 weeks [16], and 4 weeks [15].
Exclusion criteria were very strict within all studies with
pathological fractures [13e17,19e21,23,24], organ failure
or severe trauma to multiple organs [3,13,16,18e21,23,24],
mental incapacity (including dementia) [3,13e15,17,19]
and contraindication to ONSs [13e15,18e21,23,24] being
the most consistent exclusion criteria. Other exclusion
criteria included concurrent malignancy [14,15,21,23],
body mass index >25 [15], 30 [16], and 40 [23] as well as
patients that were in an unstable condition [15,16], being
treated with phenytoin, steroids, barbiturates, fluoride, or
calcitonin [13], unable to be contacted by telephone for
follow-up [16] or in need of dialysis [23]. Eneroth et al. [14]
also excluded patients who had pain or functional impair-
ment, alcohol or substance abuse, or multiple fractures as
well as patients with acute psychosis or epilepsy. Botella-
Carretero et al. [18] excluded patients with moderate to
severe malnutrition (weight loss of >5% in the previous
month or >10% in the previous 6 months, and/or serum
albumin <27 g/L) because these patients automatically
received supplementation according to the guidelines of
their institution. Pregnant patients were excluded from
Houwing et al.’s [23] study. Lastly, Schu¨rch et al. [17]
excluded those with a history of contralateral hip frac-
ture, fractures caused by severe trauma, and patients with
active metabolic bone disease, severe malnutrition, taking
drugs such as calcitonin, fluoride, sex hormones, cortico-
steroids, or bisphosphonates, or had a life expectancy of <1
year. These exclusion criteria have clear reasoning behind
them; however, studies may have excluded patients who
would benefit from ONSs. Although including dementia
patients poses an ethical dilemma, research has shown that
they are more likely to be malnourished and thus may
benefit more from such an intervention [25].Nature of intervention
All studies compared an ONS group (the intervention group)
to a control group. Most studies used hospital food as the
control group [3,13e15,18,20,21,24]; however, Neumann
et al. [16] compared a high protein ONS (Boost HP, Mead
Johnson, Evansville, IN, USA) to the “control” group, Ensure
(Ross Laboratories, Columbus, OH, USA) [16], and Espau-
lella et al. [19] compared an ONS, which provided 149 cal
including 20 g of protein to a “control” group, an ONS
containing 155 cal mainly derived from carbohydrates.
Although this provided better blinding and the consequen-
tial “placebo effect”, it can be argued that this was why
both papers lacked significant results as caloric intake by
both patient groups was increased, suggesting that
increased protein intake may not necessarily improve
clinical outcomes. Botella-Carretero et al. [18] compared
two types of ONSs, the first a protein supplement (Vegenat-
med Proteina, Vegenat SA, Badajoz, Spain) and the second
an energy and protein supplement (Resource, Hiperpro-
teico, Novartis Medical Nutrition, Barcelona, Spain) versus a
control. Lastly, Houwing et al. [23] compared an interven-
tion group to a control group that received a noncaloric-
28 M. Grigg et al.based drink containing only sweeteners, colourants, and
flavourings, thus providing a placebo and consequential
blinding of the participants.
Types of nutritional supplements
Oral nutritional supplements vary greatly with different
amounts of energy, carbohydrates, proteins, and fats.
There was little consistency between the types of supple-
ments used in the studies (see Table 1). The amount of fat
per 100 mL varied from 0 g to 4 g, whereas the carbohy-
drate content per 100 mL varied more from 7.5 g to 22.8 g.
Protein content also ranged considerably from 2.8 g to 10 g
per 100 mL.
High protein versus low protein
Only one study, Neumann et al. [16], specifically investi-
gated whether or not an ONS with increased protein levels
would be more beneficial than one without such an in-
crease. Espaulella et al. [19] did this incidentally by
providing the control group with a placebo ONS containing
no protein. Neumann et al.’s [16] study lacked any signifi-
cant results, whether this is due to an insufficient increase
in protein levels in the high protein ONS or whether
increased caloric intake as provided by ONSs increases
positive clinical outcomes regardless of formulation re-
mains to be seen. Espaulella et al. [19] only had one sig-
nificant result, that is, there was a decrease in the number
of complications in the intervention group compared to the
control group. However, the study that had the highest
level of protein, 10 g in Eneroth et al.’s [14] ONS, had very
significant results when comparing the ONS and hospital
food to just hospital food finding that the ONS reduced the
risk of fracture-related complications and reduced mor-
tality rates.
High caloric versus low caloric
Botella-Carretero et al. [18] compared two different ONSs:
the first provided 36 g of protein but only 152 kcal/day,
whereas the second provided 37.6 g of protein and 500 kcal/
day. However, significant results were only produced using
multivariate analysis; there were no other significant results
between any of the three groups. Although it is suggested
that increasing protein intake is more important than
increasing caloric intake (as other studies have implied),
further research needs to be carried out on both increases in
caloric and protein intake. Furthermore, it may be possible
that caloric intake needs to be increased by more than
500 kcal to produce significant results.
Route
The route through which the supplement was administered
differed between studies. In most studies it was given
orally; however, Eneroth et al. [14] used an intravenous
(i.v.) supplement for the 3 days following surgery as pain
limited the use of an oral supplement after which an oral
supplement was given for 7 days. Bastow et al. [3] used
nasogastric feeding using Clinifeed Iso (RousselLaboratories Ltd, Wembley Park, UK) overnight and Sullivan
et al. [21] also used nightly enteral feedings. Gunnarsson
et al. [24] used a glucose i.v. infusion preoperatively,
whereas an oral supplement was used for 5 days
postoperatively.
Timing
No study specifically investigated the effect of the timing of
ONSs. It stands to reason that providing ONSs at the same
time as normal hospital food will result in a reduction of
voluntary food intake simply due to fullness. Bastow et al.
[3], however, did note that although there was a small
decrease in voluntary intake of food in patients receiving
enteral nightly feeding it was not significant, and Delmi
et al. [13] provided the ONS at 8:00 PM so as not to interfere
with scheduled meals and thus it was found that the
voluntary oral intake was not reduced in the intervention
group. Other studies found similar findings and thus it can
be concluded that overnight feedings will not impede on
daily intake of food [26,27]. However, no other study
investigated whether the timing of ONSs affected the
normal eating habits of patients. More studies are required
to determine whether it is more beneficial to provide an
ONS overnight or during the day, prior to or after normal
meals, or between meals. Similarly, different servings of
ONSs provide different nutritional supplements, yet no
study investigated whether an increase in ONSs would in-
crease benefits in clinical outcomes or whether the in-
crease would further suppress normal caloric intake.
Data analysis
Data analysis was consistent across all studieswith nine using
the Student (unpaired) t test [3,13,15,16,19e21,23,24] and
seven using the c2 test [13e15,18,19,21,24]. The Man-
neWhitney U test was used by eight studies
[3,13e15,18,19,23,24], whereas Eneroth et al. [14], Fabian
et al. [20], and Gunnarsson et al. [24] used the paired t test.
Other tests used included the KruskaleWallis test by Myint
et al. [15] and Botella-Carretero et al. [18], the
KaplaneMeier survival test and the log rank test by Espau-
lella et al. [19] as well as the Pearson linear correlation by
Fabian et al. [20], and the van Elteren test by Neumann et al.
[16]. Gunnarsson et al. [24] used the Wilcoxon signed rank
test, whereas Botella-Carretero et al. [18] and Houwing
et al. [23] used the KolmogoroveSmirnov statistical test.
Botella-Carretero et al. [18] also used analysis of variance,
the Tukey HSD test, and a linear regression model. One-way
analysis of variance was used in Schu¨rch et al.’s [17] study.
Lastly, the Fisher exact test was used in five studies
[3,13,18,21,23]. These tests were each considered appro-
priate to the design of the study with consequential results
deemed acceptable by the respective authors.
Serum albumin levels
Serum albumin levels were used by most studies as a
method of measuring biochemical changes caused by the
ONS. Myint et al. [15] found that those in the intervention
group had a greater increase in albumin levels between
Table 1 Comparison of oral nutritional supplements (ONSs).
ONSs Used by Serving Energy Protein
(per 100 mL)
Carbohydrate
(per 100 mL)
Fat
(per 100 mL)
Vitrimix Eneroth et al. [14] 1000 mL 100 kcal/100 mL 5.3 g 7.5 g (glucose) 0.3 g
Fortimel Eneroth et al. [14] 200 mL twice daily 100 kcal/100 mL 10 g 10.3 g 2.1 g
Ensure Abbott Nutrition,
Columbus, OH, USA
Myint et al. [15] 237 mL twice daily 250 kcal/237 mL 3.7 g 16.9 g 2.6 g
Resource Breeze Myint et al. [15] 237 mL twice daily 250 kcal/237 mL 3.8 g 22.8 g 0 g
Compleat Myint et al. [15] 250 mL twice daily 106 kcal/100 mL 4.8 g 13.2 g 4 g
Glucerna Myint et al. [15] 237 mL twice daily 200 kcal/237 mL 4.2 g 11.4 g 3.0 g
Ensure Neumann et al. [16] 237 mL twice daily 250 kcal/237 mL 3.7 g 16.9 g 2.6 g
Boost HP Neumann et al. [16] 250 mL twice daily 240 kcal/250 mL 6 g 13.2 g 2.4 g
ONS Espaulella et al. [19] 200 mL daily 149 kcal/200 mL 10 g n/a n/a
ONS Fabian et al. [20] n/a 1000 kcal/1000 mL Providing 40
cal/100 mL
Providing 41
cal/100 mL
Providing 19
cal/100 mL
ONS Delmi et al. [13] 250 mL 254 kcal/250 mL 8.2 g 11.8 g 2.3 g
Clinifeed Iso Bastow et al. [3] 1000 mL 1000 kcal/1000 mL 2.8 g n/a n/a
Promote Sullivan et al. [21] 1375 mL 1031 kcal/1375 mL 6.24 g 13 g 2.6 g
ONS Gunnarsson et al. [24] Two drinks and i.v.
infusion preoperatively
100 kcal/200 mL and
50 mg glucose/mL
ONS Gunnarsson et al. [24] 200 mL three times daily 300 kcal/200 mL n/a n/a n/a
Vegenat-med Proteina Botella-Carretero
et al. [18]
10 g packets four times daily 380 kcal/100 g 9 g <0.02 0.2 g
Resource Hiperproteico Botella-Carretero
et al. [18]
200 mL twice daily 250 kcal/200 mL 9.4 g n/a n/a
Meritene Schu¨rch et al. [17] 65 g powder supplement
per day
250 kcal/serve 20 g/serve 35.7 g/serve 3.1 g/serve
Cubitan Houwing et al. [23] 400 mL daily 125 kcal/100 mL 10.0 n/a n/a
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30 M. Grigg et al.admission and 4-weeks post-discharge; however, this did
not reach significance (6.0 g/L vs. 5.0 g/L). Levels of serum
albumin were significantly greater in the intervention group
when compared with the control group at Day 14, Day 21,
and Day 180 (p < 0.05) in Delmi et al.’s [13] study. Fabian
et al. [20] found that the total protein was significantly
greater in the supplemented group when compared with
the control group at discharge (69  4 g/L vs. 64  4 g/L,
p < 0.05); however, albumin was not significantly greater in
the supplemented group when compared with the control
group despite some increase. Neumann et al. [16] found a
greater improvement in serum albumin levels in patients on
the high protein ONS (Boost HP) compared with the stan-
dard supplement Ensure ((þ7 g/L) vs. (þ2 g/L), p < 0.02).
Espaulella et al. [19] found no significant difference in al-
bumin levels between the control group and the interven-
tion group (36  6.0 g/L vs. 35  5.0 g/L). Similarly, Sullivan
et al., Eneroth et al. [14], Bastow et al. [3], Gunnarsson
et al. [24], and Schu¨rch et al. [17] found no significant
difference in serum albumin levels between the two
groups. Gunnarsson et al. [24] also investigated the effect
on serum transthyretin and serum insulin-like growth factor
1 (IGF-1). There were no significant differences in serum
transthyretin between groups; however, they found that
although serum IGF-1 decreased significantly (p < 0.001) in
the control group preoperatively to postoperatively, there
was no significant difference in the intervention group,
suggesting that low protein and energy intake results in low
serum IGF-1. Botella-Carretero et al. [18] found no signifi-
cant differences in serum albumin, serum prealbumin or
retinol-binding globulin between groups. However, by using
multivariate analysis, they were able to show that the
length of hospital stay with an established complication
until its resolution, total hospital stay, baseline body mass
index, and total daily ingested proteins per body weight
were predictive variables with regard to the change in
serum albumin (p < 0.001). Houwing et al. [23] did not
investigate the effects of ONSs on serum albumin levels.
Bone mineral density and IGF-1
Only the study by Schu¨rch et al. [17] investigated the effect
of ONS on bone mineral density (BMD). It was found that
there was no significant difference in total body BMD be-
tween the intervention group and the control group.
Schu¨rch et al. [17] also examined prealbumin levels and
IGF-1 levels and found that these levels increased signifi-
cantly in those who received the protein supplement when
compared with the control group. Furthermore, they found
that the protein supplement was associated with an almost
50% reduction of proximal femur bone loss at 1 year. A
significant increase in immunoglobulin M was also noted in
the intervention group compared with the control group.
These findings suggest that protein supplement may have
an effect on immunological status.
Infections
Infections were poorly defined in studies that investigated
the effect of supplementation on infections. Rather, in
each study infections were classified differently with somestudies focussing on specific infections, and others grouping
all infections together and some considering infections as
“complications” (see below). Eneroth et al. [14] found that
the incidence of pneumonia was significantly greater in the
control group at 10 days postoperatively (5 vs. 0, p < 0.05)
and again at 30 days postoperatively (7 vs. 0, p < 0.01).
Patients in the control group had a significantly higher
number of wound infections within 30 days compared with
those in the intervention group (12 vs. 2, p < 0.01). The
number of UTIs was significantly greater in the control
group at 120 days postoperatively (15 vs. 3 p < 0.01) but not
at any stage prior to then. Myint et al. [15] determined that
the number of infection episodes was significantly reduced
in the intervention group (14 vs. 29 in the control group,
p < 0.02); however, there were no significant differences in
individual infections nor were “infections” precisely
defined. Conversely, Neumann et al. [16], Fabian et al.
[20], Bastow et al. [3], Sullivan et al., Schu¨rch et al. [17],
and Houwing et al. [23] did not investigate the effect of
ONSs on infections. Four studies did not estimate the effect
of ONSs on infections, rather they collated complications,
including infections such as UTIs, with three finding signif-
icantly lower rates in the intervention groups [13,19,24].
The fourth study by Botella-Carretero et al. [18] found no
significant difference in infections.Complications
A number of studies focused on whether or not ONSs
reduced the number of complications in patients. Each
study defined complications differently with some including
infections as well as other major complications, including
death, and minor medical events. Espaulella et al. [19]
found that patients in the control group suffered more
complications during hospitalisation (45% vs. 31%, NS) and
over the 6-month follow-up period (70% vs. 55%, p < 0.05)
when compared with those in the intervention group. The
most common complications were delirium, UTIs, and
bedsores. Delmi et al. [13] determined that rates of com-
plications (including bedsores, severe anaemia, cardiac
failure, infection, GI ulcer) were significantly lower in the
intervention group than the control group (16% vs. 37%,
p < 0.05). Gunnarsson et al. [24] determined that females
in the control group had significantly more postoperative
complications (pressure ulcers and/or hospital-acquired
infections) than females in the intervention group
(n Z 18 vs. n Z 10, p < 0.05); however, as the male par-
ticipants who made up 30% of the groups were not included
in this statistic, it is suggested that this was not significant
overall. Eneroth et al. [14] measured complications
including thrombophlebitis, DVT, PE, pulmonary oedema,
and myocardial infarction at Day 3, Day 10, discharge, Day
30, and Day 120. It was found that at Day 120, the control
group had more complications than the intervention group;
however, this was not significant (5 vs. 1, NS). Myint et al.
[15] also found no significant results regarding complication
episodes despite the control group having twice as many
episodes (60 vs. 30, pZ 0.068). In this study, complications
included pressure sores, urinary retention, DVT, PE,
anaemia requiring transfusion or iron supplements, falls,
and electrolyte disturbances. Houwing et al. [23]
ONS in the elderly with hip fractures 31determined that although the incidence of peptic ulcers
was not significantly affected by an ONS, it was found that
it delayed the onset and progression of such a complication
in hip fracture patients; however, this did not reach sta-
tistical significance. Neumann et al. [16], Sullivan et al.,
and Botella-Carretero et al. [18] found no difference be-
tween the groups with regard to complications and Fabian
et al. [20], Bastow et al. [3], and Schu¨rch et al. [17] did not
evaluate whether the intervention reduced complication
rates.
Length of stay
Length of hospital stay and/or rehabilitation stay is a rather
good indication of a patient’s recovery speed e the earlier
they leave hospital, the faster they recover. A number of
studies [3,13e16,20] investigated the effect of ONSs on
hospital/rehabilitation stay, but it was questioned by Myint
et al. [15] whether the reduction in stay was simply sec-
ondary to a reduction in infection episodes.
Myint et al. [15] found that rehabilitation stay was
significantly reduced in the intervention group when
compared to the control group (mean Z 26.2 days vs. 29.9
days, p < 0.05). Neumann et al. [16] found that although
the length of the rehabilitation stay was shorter in the
Boost group (intervention group) it did not reach statistical
significance (meanZ 23.2 days vs. 28.0, pZ 0.27). Fabien
et al. [20] found that the average length of hospitalisation
in the intervention group was 2 days shorter than in the
control group (17  4 days vs. 19  9 days). They also
determined that the length of hospital stay was positively
correlated with increased levels of oxidative stress but
negatively associated with albumin and total antioxidant
capacity (the ONS was found to decrease levels of oxidative
stress and increase levels of albumin and total antioxidant
capacity). Length of hospital stay was also found to be
significantly shorter in the intervention group when
compared to the control group (24 days vs. 40 days,
p < 0.02) in Delmi et al.’s [13] study. Bastow et al. [3] found
that those in the tube fed group had a shorter hospital stay
than those who were in the control group (median hospital
stay of 29 days vs. 38 days, pZ 0.04). Shorter rehabilitation
stays were found to be significantly shorter in the inter-
vention group when compared with the control (42.2  6.6
days vs. 53.0  4.6 days, p < 0.02) in Schu¨rch et al.’s [17]
study; however, it was also found that there was no sig-
nificant difference in the length of hospital stays. Eneroth
et al. [14] found no difference between lengths of hospital
stay between groups with 12.5 days being the mean for
both, whereas discharge rates were not significantly
different in Sullivan et al.’s study. Hospital stays were
similar in all three groups in Botella-Carretero et al.’s [18]
study. Espaulella et al. [19], Gunnarsson et al. [24], and
Houwing et al. [23] did not investigate the effect of ONSs on
length of hospital stay.
Clinical outcome
Only two studies investigated the effect of ONSs on clinical
outcomes of patients, the remainder did not specifically
evaluate whether clinical outcomes could be improvedthrough the use of ONSs. It was found that the clinical
outcome in the intervention group in Delmi et al.’s [13]
study was much better during their hospital stay with 56%
having a positive course (i.e., had one “minor” complica-
tion, e.g., lower UTI or none) compared with 13% of the
control group. Neumann et al. [16] found no statistically
significant improvement in clinical outcomes using the
Functional Independence Measure between the two types
of ONSs, a standard supplement and a high protein sup-
plement; whether an improvement would have occurred
compared with hospital food is unknown.
Mortality
Seven of the 12 studies investigated the effect of ONSs on
mortality rates [3,13e15,17,19,21]. However, only three of
these found significant results [13,14,20]. Four patients
(10%) in the Eneroth et al.’s [14] control group died,
whereas there were no deaths in the intervention group
(p < 0.04). One death was from general weakness and
malnourishment, whereas the other three were due to
pneumonia. This leads to the question whether it was the
reduction in complications (i.e., pneumonia), which was
also significant in this study, that caused the reduction in
mortality or whether there is a direct link between the use
of ONSs and mortality. Delmi et al. [13] found that patients
in the control group had a significantly higher mortality rate
(37%) when compared with those in the intervention group
(24%). In Sullivan et al.’s first feasibility study it was found
that the mortality rate in the control group (50%, nZ 5 out
of 10) significantly far exceeded the rate in the intervention
group (0%) [21]. However, in the follow-up study conducted
6 years later, no significance was found between mortality
rates [22]. Myint et al. [15], Espaulella et al. [19], Bastow
et al. [3], and Schu¨rch et al. [17] all found similar mortality
rates between the two groups. This even divide indicates
that the effect of ONSs is still unknown and further research
needs to be undertaken and possibly investigate the effect
of different types of ONSs including high protein on
mortality.
Malnutrition and infection
Studies have investigated the effect of malnutrition on the
body’s ability to combat infections. Keenan et al. [28]
found that protein calorie malnutrition and deficiency in
fatty acids, vitamins, and trace elements impaired cytokine
production. Cytokines are soluble factors necessary for the
communication between different cells required for an
immune response. Some cytokines [e.g., interleukin 1 (IL-1)
and tumour necrosis factor] are preformed but most require
transcription of cytokine genes and subsequent translation
of mRNA into protein to be formed. Furthermore, they
found that patients who were receiving inadequate levels
of proteins and calories had a reduced ability to synthesise
IL-1a, which is necessary for inducing the synthesis of acute
phase proteins. It was found that the ability to produce IL-1
correlates with dietary protein intake and was also associ-
ated with improved survival [28]. Munoz et al. [29] deter-
mined that IL-1b levels, which were low in malnutrition
patients, increased significantly after 4 months of
32 M. Grigg et al.nutritional rehabilitation. Low IL-1 activity was conse-
quently able to explain the impaired ability for malnour-
ished patients to mount a febrile response to infectious
agents, which increases their risk for mortality [29].
In animal experiments, protein depletion caused an
inability for rabbits to mount a febrile response to Gram-
negative infections [30], whereas peritoneal macrophages
from protein-depleted guinea pigs were unable to produce
IL-1 [31]. Individual amino acids were found to have a direct
influence on the immune system. Glutamine stimulates
growth hormone, which directly and indirectly increases
function of the immune system. Normally able to be syn-
thetized by the body during stress, the body’s demand for it
exceeds its ability to create it, thus as a now essential
nutrient, it is necessary for the catabolic process to pro-
duce optimal tissue response to infection as well as
inflammation and catabolism. Glutamine was also found to
increase neutrophils ability to kill Staphylococcus aureus
[32]. Arginine, an essential amino acid, has been found to
minimise negative nitrogen balance, stimulate the immune
system, and improve wound healing. The latter is enabled
as arginine stimulates growth hormone, glucagon, prolac-
tin, and insulin [33].
It is not just a lack of macronutrients that have been
implicated in increased infection susceptibility. Vitamin E
is the most effective chain breaking, lipid-soluble antiox-
idant in biological membranes of all cells. Because of their
high polyunsaturated fatty acid content, immune cells are
at high risk for oxidative damage, thus they are enriched
with large amounts of Vitamin E. Lack of vitamin E
consequently incurs damage. Thus, vitamin E supplemen-
tation has found to improve immune function in the elderly
and increase cell division and IL-producing capabilities of
naı¨ve T cells. This has been associated with significant
improvement in resistance to influenza virus infection in
aged mice and a reduced risk of acquiring upper respira-
tory tract infections in nursing home residents. There are
several possible mechanisms as to why vitamin E is able to
stimulate the immune system. One possible mechanism is
the ability of vitamin E to enhance T cell mediated func-
tion by directly influencing membrane integrity and signal
transduction in T cells. Another is by indirectly reducing
the production of suppressive factors, such as prosta-
glandin E2 (PGE2), by macrophages. PGE2 is upregulated in
the elderly, thus leading to the suppression of T cell im-
munity, by using supplements, vitamin E is able to prevent
this suppression thus increasing the patient’s ability to
combat infections [34]. Another important micronutrient is
zinc. Zinc deficiency has been found to reduce nonspecific
immunity, including neutrophil and natural killer cell
function and complement activity. It also reduces the
numbers of T lymphocytes and B lymphocytes and sup-
presses delayed hypersensitivity, cytotoxic activity, and
antibody production. Low zinc has also been found spe-
cifically in patients with pneumonia [35]. These studies,
although suggesting the importance of specific macronu-
trients and micronutrients in fighting infections, have yet
to be applied to human participants and specifically pa-
tients who have suffered from a hip fracture. By providing
ONSs aiming to fill deficiencies of these nutrients, it is
proposed that the patient’s ability to combat infections
will be increased.Malnutrition and fracture healing
Animal studies have demonstrated the adverse effects of
malnutrition and vitamin(s) deficiency on fracture healing.
However, there is little information on whether these re-
sults correspond to human participants and whether the
correction of such deficiencies will improve clinical out-
comes. Pollak et al. [36] investigated the effect of different
nutritional regimens on fracture healing in rats. It was
determined that those who received low protein levels (5%
of diet) resulted in significantly lower tensile strength and
stiffness of calluses despite adequate caloric intake when
compared with three other diets all consisting of greater
levels of protein. Furthermore, this low protein diet resul-
ted in a callus with “rubbery” mechanical properties rather
than the “rigid” calluses of the other groups. Hughes et al.
[37] also found that rats on a 30% protein diet had increased
levels of albumin and BMD in the fracture callus when
compared with rats on a 6% protein diet. However, there
were no significant differences in biomechanical testing of
the fracture. Finally, Guarniero et al. [38] determined that
rats subjected to protein malnutrition prior to and after a
fracture had abnormal callus development, and Rodrigues
et al. [39] found that undernutrition produced a delay in
callus formation in rats. Dwyer et al. [40] attempted to
correlate the nutritional status of patients and the union of
open fractures; however, they found no significant results
relating malnutrition to bone union.
Malnutrition and sarcopenia
The relation of malnutrition to sarcopenia with conse-
quential frailty in elderly patients has been established
[41,42]. Furthermore, decreased lower extremity strength
has been found to be a risk factor for injurious falls in the
year after suffering a hip fracture, whereas malnutrition
was found to be a risk factor for recurrent falls resulting in
fracture [43]. However, the effects of ONSs and whether
they are capable in reversing sarcopenia, especially in
elderly hip fracture patients, has yet to be researched.
Discussion
Despite the elderly population expected to increase
considerably, there is limited research evaluating the role
of ONSs on hip fractures and ways to reduce complications,
expensive hospital stays and, most importantly, mortality.
The research that has been completed shows mixed results,
with some finding entirely significant results and others
finding no significant results. Furthermore, the majority of
articles excluded important patients e those who suffered
from dementia and/or were mentally incompetent to
participate in the research. Although this does pose an
ethical issue, it also precludes patients that are more likely
to be suffering from malnutrition and thus in greater need
of nutritional supplements [25].
Another issue found in the inclusion of all appropriate
candidates was that of time, money, and protocol. Sullivan
et al. were only able to enter patients from Monday to
Friday, whereas Bastow et al. [3] were only able to include
six patients at any one time, thus reducing the likelihood of
ONS in the elderly with hip fractures 33all patients who met the inclusion criteria being included in
the study. Such constraints due to time and hospital pro-
tocol and staffing cause a reduction in numbers that could
have increased the significance of the results. Lastly,
Botella-Carretero et al. [18] were unable to include
malnourished patients in their trial because of hospital
protocol stating that all malnourished patients must receive
nutritional supplementation. Consequently, from their
mostly nonsignificant results, it can be concluded that ONSs
do not have the same effect on nourished patients as they
would on malnourished patients.
Lastly, although there has been much research on the
effects of specific vitamins and minerals on immunity and
reducing infections, it has yet to be applied to specific
cases such as hip fractures. Furthermore, it can be sur-
mised that the detrimental effects of malnutrition on
fracture healing has well been demonstrated in animal
participants; however, further research is necessary to
make the connection between malnutrition and clinical
outcomes in human participants and specifically those with
hip fractures. Finally, it is yet to be determined whether
ONSs are able to reverse sarcopenia and if so whether this
has a positive effect on clinical outcomes for hip fracture
patients.
There is a need to better understand the effect of
nutritional supplements on reducing the risks of infections/
complications, rehabilitation/hospital stay and, most
importantly, mortality in elderly patients. Nutritional sup-
plements may have the potential to significantly improve
the quality of life in patients who suffer an unfortunately
common ailment in their old age. Furthermore, relatively
inexpensive supplements have the possible capability of
reducing the cost of treating infections and maintaining
hospital beds for increased periods of time.
Additionally, more research is required on when to
provide ONSs, for what period of time, how much to give,
and the patients who need it the most e those who are
malnourished or all patients. Lastly, more studies are
required on whether an ONS with higher levels of protein is
actually significantly better than an ONS with little or no
protein.
Studies evaluating the effects of a variety of different
supplements against a control group (hospital food only) on
infection and complication rates both in and out of the
hospital, functional status measured at different time in-
tervals after the operation, length of hospital, and reha-
bilitation stay and, finally, mortality are recommended to
definitively determine whether or not nutritional supple-
ments are beneficial.
In conclusion, there is very little work that can prove the
benefits of elderly patients using nutritional supplements
who are suffering from hip fractures. Consequently, more
studies are needed to understand the effects of ONSs used
in everyday hospital treatment on preventing complications
and mortality in patients with hip fractures and reducing
hospital stays.
Conflicts of interest
No authors have received anything of value in relation to
this work and there are no conflicts of interest.References
[1] Statistics ABo. Population projections, Australia, 2006 to 2101
(updated July 6, 2011; cited February 23, 2013); available from:
http://www.abs.gov.au/ausstats/abs@.nsf/mf/3222.0; 2008.
[2] Sanders KM, Nicholson GC, Ugoni AM, Pasco JA, Seeman E,
Kotowicz MA. Health burden of hip and other fractures in
Australia beyond 2000. Projections based on the Geelong
Osteoporosis Study. Med J Aust 1999;170:467e70.
[3] Bastow MD, Rawlings J, Allison SP. Benefits of supplementary
tube feeding after fractured neck of femur: a randomised
controlled trial. Br Med J 1983;287:1589e92.
[4] Philipson TJ, Snider JT, Lakdawalla DN, Stryckman B,
Goldman DP. Impact of oral nutritional supplementation on
hospital outcomes. Am J Manag Care 2013;19:121e8.
[5] Stratton RJ, Ek AC, Engfer M, Moore Z, Rigby P, Wolfe R, et al.
Enteral nutritional support in prevention and treatment of
pressure ulcers: a systematic review and meta-analysis.
Ageing Res Rev 2005;4:422e50.
[6] Bozzetti F, Gavazzi C, Miceli R, Rossi N, Mariani L, Cozzaglio L,
et al. Perioperative total parenteral nutrition in malnour-
ished, gastrointestinal cancer patients: a randomized, clinical
trial. J Parenter Enteral Nutr 2000;24:7e14.
[7] Milne AC, Avenell A, Potter J. Meta-analysis: protein and energy
supplementation in older people. Ann Intern Med 2006;144:
37e48.
[8] VonMeyenfeldt MF, MeijerinkWJ, Rouflart MM, BuilmaassenMT,
Soeters PB. Perioperative nutritional support: a randomised
clinical trial. Clin Nutr 1992;11:180e6.
[9] Keele AM, Bray MJ, Emery PW, Duncan HD, Silk DB. Two phase
randomised controlled clinical trial of postoperative oral di-
etary supplements in surgical patients. Gut 1997;40:393e9.
[10] Saluja SS, Kaur N, Shrivastava UK. Enteral nutrition in surgical
patients. Surg Today 2002;32:672e8.
[11] The Veterans Affairs Total Parenteral Nutrition Cooperative
Study Group. Perioperative total parenteral nutrition in sur-
gical patients. N Engl J Med 1991;325:525e32.
[12] Hartgrink HH, Wille J, Konig P, Hermans J, Breslau PJ. Pres-
sure sores and tube feeding in patients with a fracture of the
hip: a randomized clinical trial. Clin Nutr 1998;17:287e92.
[13] Delmi M, Rapin CH, Bengoa JM, Delmas PD, Vasey H,
Bonjour JP. Dietary supplementation in elderly patients with
fractured neck of the femur. Lancet 1990;335:1013e6.
[14] Eneroth M, Olsson UB, Thorngren KG. Nutritional supplemen-
tation decreases hip fracture-related complications. Clin
Orthop Relat Res 2006;451:212e7.
[15] Myint MW, Wu J, Wong E, Chan SP, To TS, Chau MW, et al.
Clinical benefits of oral nutritional supplementation for
elderly hip fracture patients: a single blind randomised
controlled trial. Age Ageing 2013;42:39e45.
[16] Neumann M, Friedmann J, Roy MA, Jensen GL. Provision of
high-protein supplement for patients recovering from hip
fracture. Nutrition 2004;20:415e9.
[17] Schu¨rch MA, Rizzoli R, Slosman D, Vadas L, Vergnaud P,
Bonjour JP. Protein supplements increase serum insulin-like
growth factor-I levels and attenuate proximal femur bone loss
inpatientswith recenthip fracture.A randomized, double-blind,
placebo-controlled trial. Ann Intern Med 1998;128:801e9.
[18] Botella-Carretero JI, Iglesias B, Balsa JA, Zamarron I,
Arrieta F, Vazquez C. Effects of oral nutritional supplements in
normally nourished or mildly undernourished geriatric pa-
tients after surgery for hip fracture: a randomized clinical
trial. J Parenter Enteral Nutr 2008;32:120e8.
[19] Espaulella J, Guyer H, Diaz-Escriu F, Mellado-Navas JA,
Castells M, Pladevall M. Nutritional supplementation of
elderly hip fracture patients. A randomized, double-blind,
placebo-controlled trial. Age Ageing 2000;29:425e31.
34 M. Grigg et al.[20] Fabian E, Gerstorfer I, Thaler HW, Stundner H, Biswas P,
Elmadfa I. Nutritional supplementation affects postoperative
oxidative stress and duration of hospitalization in patients
with hip fracture. Wien Klin Wochenschr 2011;123:88e93.
[21] Sullivan DH, Nelson CL, Bopp MM, Puskarich-May CL, Walls RC.
Nightly enteral nutrition support of elderly hip fracture pa-
tients: a phase I trial. J Am Coll Nutr 1998;17:155e61.
[22] Sullivan DH, Nelson CL, Klimberg VS, Bopp MM. Nightly enteral
nutrition support of elderly hip fracture patients: a pilot
study. J Am Coll Nutr 2004;23:683e91.
[23] Houwing RH, Rozendaal M, Wouters-Wesseling W, Beulens JW,
Buskens E, Haalboom JR. A randomised, double-blind assess-
ment of the effect of nutritional supplementation on the
prevention of pressure ulcers in hip-fracture patients. Clin
Nutr 2003;22:401e5.
[24] Gunnarsson AK, Akerfeldt T, Larsson S, Gunningberg L.
Increased energy intake in hip fracture patients affects nutri-
tional biochemical markers. Scand J Surg 2012;101:204e10.
[25] Hickson M. Malnutrition and ageing. Postgrad Med J 2006;82:
2e8.
[26] Ashworth N, Creedys Hunt JN, Mahon S, Newland P. Effect of
nightly food supplements on food intake in man. Lancet 1962;
2:685e7.
[27] Yeung CK, Young GA, Hackett AF, Hill GL. Fine needle catheter
jejunostomy e an assessment of a new method of nutritional
support after major gastrointestinal surgery. Br J Surg 1979;
66:727e32.
[28] Keenan RA, Moldawer LL, Yang RD, Kawamura I, Blackburn GL,
Bistrian BR. An altered response by peripheral leukocytes to
synthesize or release leukocyte endogenous mediator in crit-
ically ill, protein-malnourished patients. J Lab Clin Med 1982;
100:844e57.
[29] Munoz C, Schlesinger L, Cavaillon JM. Interaction between
cytokines, nutrition and infection. Nutr Res 1995;15:1815e44.
[30] Hoffman-Goetz L, Kluger MJ. Protein deficiency: its effects on
body temperature in health and disease states. Am J Clin Nutr
1979;32:1423e7.
[31] Moldawer LLG, Georgieff M, Hamawy KJ, Blackburn GL,
Bistrian BR. Therapeutic administration of interleukin 1 toimmunocompromised animals. Br J Rheumatol 1985;24:
220e4.
[32] Wilmore DW, Shabert JK. Role of glutamine in immunologic
responses. Nutrition 1998;14:618e26.
[33] Felblinger DM. Malnutrition, infection, and sepsis in acute and
chronic illness. Crit Care Nurs Clin North Am 2003;15:71e8.
[34] Meydani SN, Han SN, Wu D. Vitamin E and immune response in
the aged: molecular mechanisms and clinical implications.
Immunol Rev 2005;205:269e84.
[35] Katona P, Katona-Apte J. The interaction between nutrition
and infection. Clin Infect Dis 2008;46:1582e8.
[36] Pollak D, Floman Y, Simkin A, Avinezer A, Freund HR. The
effect of protein malnutrition and nutritional support on the
mechanical properties of fracture healing in the injured rat. J
Parenter Enteral Nutr 1986;10:564e7.
[37] Hughes MS, Kazmier P, Burd TA, Anglen J, Stoker AM, Kuroki K,
et al. Enhanced fracture and soft-tissue healing by means of
anabolic dietary supplementation. J Bone Joint Surg Am 2006;
88:2386e94.
[38] Guarniero R, de Barros Filho TE, Tannuri U, Rodrigues CJ,
Rossi JD. Study of fracture healing in protein malnutrition. Rev
Paul Med 1992;110:63e8.
[39] Rodrigues L, Correa L, Luz JG. Healing of displaced condylar
process fracture in rats submitted to protein undernutrition. J
Craniomaxillofac Surg 2011;39:73e8.
[40] Dwyer AJ, John B, Mam MK, Antony P, Abraham R, Joshi M.
Relation of nutritional status to healing of compound fractures
of long bones of the lower limbs. Orthopedics 2007;30:709e12.
[41] Morley JE. Sarcopenia in the elderly. Fam Pract 2012;
29(Suppl. 1):i44e8.
[42] Aras S, Yalcin A, Varil M, Cengiz Karaarslan O, Atmis V, Atli T.
Sarcopenia prevalence and sarcopenia related clinical condi-
tions in elderly nursing home residents. Eur Geriatr Med 2013;
4(Suppl 1):S20e1.
[43] Lloyd BD, Williamson DA, Singh NA, Hansen RD, Diamond TH,
Finnegan TP, et al. Recurrent and injurious falls in the year
following hip fracture: a prospective study of incidence and
risk factors from the Sarcopenia and Hip Fracture study. J
Gerontol A Biol Sci Med Sci 2009;64:599e609.
